KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Total Debt (2016 - 2025)

Abbott Laboratories' Total Debt history spans 17 years, with the latest figure at $12.9 billion for Q4 2025.

  • For Q4 2025, Total Debt fell 8.47% year-over-year to $12.9 billion; the TTM value through Dec 2025 reached $12.9 billion, down 8.47%, while the annual FY2025 figure was $12.9 billion, 8.47% down from the prior year.
  • Total Debt for Q4 2025 was $12.9 billion at Abbott Laboratories, roughly flat from $12.9 billion in the prior quarter.
  • Across five years, Total Debt topped out at $18.3 billion in Q2 2021 and bottomed at $12.9 billion in Q4 2025.
  • The 5-year median for Total Debt is $16.0 billion (2022), against an average of $15.7 billion.
  • The largest annual shift saw Total Debt rose 4.0% in 2021 before it decreased 13.69% in 2024.
  • A 5-year view of Total Debt shows it stood at $18.0 billion in 2021, then decreased by 7.07% to $16.8 billion in 2022, then fell by 12.48% to $14.7 billion in 2023, then dropped by 3.77% to $14.1 billion in 2024, then dropped by 8.47% to $12.9 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Total Debt are $12.9 billion (Q4 2025), $12.9 billion (Q3 2025), and $13.4 billion (Q2 2025).